- GlobeNewswire•9 days ago
Strong Momentum for Galafold Launch in Europe and Multiple Global Regulatory Submissions Ahead. Additional Data from Pompe Phase 1/ 2 Clinical Study and Top-Line Data from Phase 3 Epidermolysis Bullosa ...
- 24/7 Wall St.•10 days agoHuge Energy Trade Kicks Off 2017 Insider Buying: DCP Midstream, Och-Ziff Capital, TransEnterix, Amicus Therapeutics and More
The volume of insider activity has started to dry up as we get closer to the fourth-quarter earnings reports, and as usual, it could stay low most of the month of January.
- GlobeNewswire•14 days agoNational Institute for Health and Care Excellence (NICE) Issues Final Positive Recommendation for Galafold™ (migalastat) for Fabry Disease in England
Reimbursement Secured for Patients in England. Commercial Launch in England, Wales and Northern Ireland Anticipated in Early 2017. CRANBURY, N.J., Jan. 04, 2017-- Amicus Therapeutics, a global biotechnology ...
FOLD: Summary for Amicus Therapeutics, Inc. - Yahoo Finance
Amicus Therapeutics, Inc. (FOLD)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
|Bid||5.27 x 2900|
|Ask||5.28 x 8000|
|Day's range||5.23 - 5.42|
|52-week range||4.41 - 9.83|
Trade prices are not sourced from all markets
|PE ratio (TTM)||-3.73|
|Dividend & yield||N/A (N/A)|
|1y target est||N/A|